Patent ID: 6596735
Filing Date: 2003-07-22
Classification: A61P,C07D

Abstract:
A compound of the formula: or a pharmaceutically acceptable salt or solvate thereof wherein:Y is â€”(CR13R14)nâ€” or â€”NR13â€”, wherein n is 1 or 2; R1 is H, â€”(CR13R14)â€”Oâ€”(C1-C6)alkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, â€”C(O)NR13R14, â€”C(O)R13, â€”C(O)OR13, â€”OC(O)R13, â€”C(O)NR13R14, C3-C6 cycloalkyl, phenyl, or â€”(4 to 6 membered heterocyclic); and wherein when Y is â€”(CR13R14)nâ€” then R1 can be further selected from â€”NR13R14, nitro, hydroxy, and azido; and wherein alkyl, cycloalkyl, phenyl, and heterocyclic moieties of the aforementioned R1 substituents are optionally substituted with from one to three halogens; R2 is H, halo, cyano, R11 or â€”C(O)OR11, wherein cycloalkyl, aryl and heterocyclic moieties of said R2 groups are optionally fused to a C6-C10 aryl group, a C5-C8 saturated cyclic group, or a 4 to 10 membered heterocyclic group, and wherein the foregoing R2 groups, except H, halo, and cyano, but including any optional fused rings, are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, â€”C(O)R13, â€”C(O)OR13, â€”OC(O)R13, â€”NR13C(O)R14, â€”C(O)NR13R14, â€”NR13R14, hydroxy, C1-C6 alkyl, and C1-C6 alkoxy; each R3, R4, R5, R6, and R7 is independently selected from H, R11, C2-C10 alkenyl, C2-C10alkynyl, halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, hydroxy, â€”OR11, â€”C(O)H, â€”C(O)OH, â€”C(O)R11, â€”C(O)OR11, â€”NR13C(O)OR11, â€”OC(O)H, â€”OC(O)R11, â€”NR13SO2R11, â€”SO2NHR13, â€”SO2NR11R13, â€”NR13C(O)H, â€”NR13C(O)R11, â€”C(O)NR13H, â€”C(O)NR11R13, â€”NHR13, â€”NR11R13, â€”CH&boxH;NOH, â€”CH&boxH;NOR11, â€”S(O)jH, â€”S(O)jR11, wherein j is an integer frdm 0 to 2, â€”(CR13R14)tCâ‰¡CH, â€”(CR13R14)tCâ‰¡CR11, â€”(CR13R14)tCâ‰¡CSiH2(R11), â€”(CR13R14)tCâ‰¡CSiH(R11)2, and â€”(CR13R14)tCâ‰¡CSi(R11)3; and wherein alkyl, alkenyl, cycloalkyl, aryl, and heterocyclic moieties of the foregoing R3, R4, R5, R6, and R7 groups are optionally substituted by 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, â€”NR13SO2(C1-C6 alkyl), â€”SO2NR13R14, â€”C(O)H, â€”C(O)(C1-C6 alkyl), â€”C(O)OH, â€”C(O)O(C1-C6 alkyl), â€”OC(O)H, â€”OC(O)(C1-C6 alkyl), â€”NR13C(O)O(C1-C6 alkyl), â€”NR13C(O)H, â€”NR13C(O)(C1-C6 alkyl), â€”C(O)NR13R14, â€”NR13R14, hydroxy, C1-C6 alkoxy, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, â€”(CR13R14)t(C6-C10), â€”(CR13R14)t(C3-C10 cycloalkyl), and â€”(CR13R14)t(4 to 10 membered heterocyclic); R8 is H, cyano, hydroxy, â€”(CR13R14)t(4 to 10 membered heterocyclic), â€”OR11, â€”OC(O)H, â€”OC(O)R11, â€”NR13H, â€”NR11R13, â€”NR13C(O)H, â€”C(O)OH, â€”C(O)OR11, â€”SH, or â€”SR11, wherein heterocyclic groups of said R8 groups are optionally substituted by 1 to 4 R6 groups; R9 is â€”(CR13R14)t(imidazolyl) or â€”(CR13R14)t(pyridinyl), wherein said imidazolyl or pyridinyl moiety is optionally substituted by 1 or 2 R6 substituents; R10 is phenyl or an aromatic 4 to 10 membered heterocyclic group, and said R10 group is optionally substituted by 1 to 4 R6 substituents; each R11 is independently C1-C10 alkyl, â€”(CR13R14)t(C3-C10 cycloalkyl), â€”(CR13R14)t(C6-C10 aryl), or (CR13R14)t(4 to 10 membered heterocyclic); each R13 and R14 is independently H or C1-C3 alkyl; and each t is an integer independently selected from 0 through 4.